source
- AstraZeneca halts late-stage trial of volrustomig in metastatic lung cancerAstraZeneca said it is stopping a late-stage study of its experimental drug volrustomig combined with chemotherapy in patients with metastatic non-small cell lung cancer. The company made the decis…
- AstraZeneca halts late-stage lung cancer trial of volrustomig after disappointing interim resultsAstraZeneca announced it is stopping a Phase 3 study of its bispecific antibody volrustomig in metastatic non-small cell lung cancer after an interim analysis showed the drug is unlikely to meet it…